Network origin in Markus Rüegg first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Neurotune AG
 Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Markus Rüegg via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
| University of Zurich | College/University | Doctorate Degree Corporate Officer/Principal | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal | |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Founder | |
| SPEXIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Groningen | College/University | Doctorate Degree | |
Institut Straumann AG
 Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Medical/Nursing Services | Director of Finance/CFO | |
| AC IMMUNE SA | Pharmaceuticals: Major | Chief Operating Officer | |
| International Institute for Management Development | College/University | Masters Business Admin | |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer | |
Qvanteq AG
 Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Biotechnology | Founder |
Statistics
International
| Switzerland | 11 |
| United States | 2 |
| Netherlands | 2 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 6 |
| Health Services | 2 |
Operational
| Corporate Officer/Principal | 5 |
| Chairman | 4 |
| Founder | 4 |
| Doctorate Degree | 3 |
| Chief Executive Officer | 3 |
Most connected contacts
| Insiders | |
|---|---|
| Armin W. Mäder | 7 |
| Bruno Oesch | 6 |
| Jan Willem Vrijbloed | 4 |
| Cornel Sieber | 1 |
- Stock Market
- Insiders
- Markus Rüegg
- Company connections
